4//SEC Filing
Poulton Stuart 4
Accession 0000950170-25-023192
CIK 0001503802other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 4:17 PM ET
Size
4.8 KB
Accession
0000950170-25-023192
Insider Transaction Report
Form 4
Poulton Stuart
EVP, Chief Development Officer
Transactions
- Sale
Common Stock
2025-02-18$0.63/sh−5,914$3,726→ 320,714 total
Footnotes (1)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Documents
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001942597
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 4:17 PM ET
- Size
- 4.8 KB